Sarm1 enzyme activity inhibitor and application thereof
US-2024368168-A1 · Nov 7, 2024 · US
US9250237B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9250237-B2 |
| Application number | US-201113990396-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 29, 2011 |
| Priority date | Nov 30, 2010 |
| Publication date | Feb 2, 2016 |
| Grant date | Feb 2, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided are novel types of hybrid cyclic libraries that contain a known protein binding domain of a natural product. Also provided are synthetic methods to make such libraries and methods for the deconvolution of hits using partially split-pooled library compounds. Such methods are applicable for use with the entire human proteome to screen such libraries that bind and for the identification of hits.
Opening claim text (preview).
What is claimed is: 1. A compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: is a single or double bond; X 1 is O or NR 6 ; Y is —C(O)— or X 2 is (CH 2 ) m , O, or NR 6 ; Z is W is O, CH, CH 2 , CR 4 , or CR 5 ; L 1 and L 2 are each independently a direct bond, substituted or unsubstituted —(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n O(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)—, substituted or unsubstituted —(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)O(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n NH(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)NH(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n S(C 1 -C 6 )alkyl-, substituted or unsubstituted —(CH 2 ) n C(O)(CH 2 ) n S(C 1 -C 6 )alkyl-, substituted or unsubstituted —(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n O(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)O(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n NH(C 1 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)NH(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n S(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(CH 2 ) n C(O)(CH 2 ) n S(C 2 -C 6 )alkenyl-, substituted or unsubstituted —(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 )—O(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)O(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n NH(C 1 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)NH(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n S(C 2 -C 6 )alkynyl-, substituted or unsubstituted —(CH 2 ) n C(O)(CH 2 ) n S(C 2 -C 6 )alkynyl-, wherein each alkyl, alkenyl and alkynyl group may be optionally substituted with alkyl, alkoxy, amino, carboxyl, cyano, nitro, or trifluoromethyl; each m is independently an integer selected from 0, 1, 2, 3, 4, 5, and 6; each n is independently an integer selected from 0, 1, 2, 3, 4, 5, and 6; R 1 is hydrogen, hydroxyl, or OPG, wherein PG is a protecting group, or R 1 is wherein is a resin; R 2 is hydrogen, hydroxyl, or alkoxy; R 3 is hydrogen or alkyl; R 4 and R 5 are each independently hydrogen, hydroxy, alkyl, alkoxy, or OPG, wherein PG is a protecting group; R 6 is hydrogen or alkyl; wherein the Effector Domain has Formula II: wherein: R 7 , R 9 , R 11 , R 13 , and R 15 are each independently hydrogen or alkyl; R 8 , R 10 , R 12 , and R 14 are each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted perfluoroalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted aryl, substituted or unsubstituted alkylaryl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroalkylaryl, (CH 2 ) n CN, (CH 2 ) n CF 3 , (CH 2 ) n C 2 F 5 , (CH 2 ) n OR 16 , (CH 2 ) n C(O)R 16 , (CH 2 ) n C(O)OR 16 , (CH 2 ) n OC(O)R 16 , (CH 2 ) n NR 17 R 18 , (CH 2 ) n C(O)NR 17 R 18 , (CH 2 ) n N 19 RC(O)R 16 , (CH 2 ) n N 19 RC(O)OR 16 , (CH 2 ) n NR 19 C(O)NR 17 R 18 , (CH 2 ) n SR 16 , (CH 2 ) n S(O) j NR 17 R 18 , (CH 2 ) n N 19 RS(O) j R 16 , or —(CH 2 ) n NR 19 S(O) j NR 17 R 18 ; n is an integer selected from 0, 1, 2, 3, 4, 5, and 6; j is an integer selected from 0, 1, and 2; R 16 , R 17 , R 18 , and R 19 are each independently hydrogen, halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, or heteroalkylaryl, or R 16 and R 19 are as described above, and R 17 and R 18 , together with the N atom to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered heterocycloalkyl or a substituted or unsubstituted 5-membered heteroaryl, wherein each of the above groups listed for R 8 , R 10 , R 12 , and R 14 may be optionally independently substituted with 1 to 3 groups selected from halogen, amino, cyano, nitro, trifluoromethyl, alkyl, alkenyl, alkynyl, cycloalkyl, perfluoroalkyl, alkoxy, alkylamino, alkylthio, aryl, alkylaryl, heteroalkyl, heterocycloalkyl, heteroaryl, heteroalkylaryl, (CH 2 ) n CN, (CH 2 ) n CF 3 , (CH 2 ) n C 2 F 5 , (CH 2 ) n OR 16 , (CH 2 ) n C(O)R 16 , (CH 2 ) n C(O)OR 16 , (CH 2 ) n OC(O)R 16 , (CH 2 ) n NR 17 R 18 , (CH 2 ) n C(O)NR 17 R 18 , (CH 2 ) n N 19 RC(O)R 16 , (CH 2 ) n N 19 RC(O)OR 16 , (CH 2 ) n NR 19 C(O)NR 17 R 18 , (CH 2 ) n SR 16 , (CH 2 ) n S(O) j NR 17 R 18 , (CH 2 ) n N 19 RS(O) j R 16 , and —(CH 2 ) n NR 19 S(O) j NR 17 R 18 . 2. The compound of Formula I of claim 1 , wherein: X is O or NR 6 ; L 1 and L 2 are each independently —(C 1 -C 6 )alkyl-, —(CH 2 ) n O(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)O(C 1 -C 6 )alkyl-, —(CH 2 ) n NH(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)NH(C 1 -C 6 )alkyl-, —(CH 2 ) n S(C 1 -C 6 )alkyl-, —(CH 2 ) n C(O)(CH 2 ) n S(C 1 -C 6 )alkyl-, —(C 2 -C 6 )alkenyl-, —(CH 2 ) n O(C 2 -C 6 )alkenyl-, —(CH 2 ) n C(O)(C 2 -C 6 )alkenyl-, —(CH 2 ) n C(O)O(C 2 -C 6 )alkenyl-, —(CH 2 ) n NH(C 1 -C 6 )alkenyl-, —(CH 2 ) n C(O)NH(C 2 -C 6 )alkenyl-, —(CH 2 ) n S(C 2 -C 6 )alkenyl-, (CH 2 ) n C(O)(CH 2 ) n S(C 2 -C 6 )alkenyl-, wherein each alkyl and alkenyl group may be substituted with alkyl, alkoxy, or carboxyl; n is an integer selected from 0, 1, 2, 3, 4, 5, and 6; R 1 is hydrogen, hydroxyl, or OPG, wherein PG is a silyl protecting group, or R 1 is wherein is a resin; R 2 is hydroxyl or alkoxy; R 3 is hydrogen or alkyl; R 4 and R 5 are each independently hydrogen, alkyl, alkoxy, or OPG, wherein PG is a silyl protecting group; R 6 is hydrogen; R 7 , R 9 , R 11 , R 13 , and R 15 are each independently hydrogen or CH 3 ; R 8 , R 10 , R 12 , and R 14 are each independently substituted or unsubstituted cyclopropyl, substituted or unsubstituted cyclobutyl, substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted cycloheptyl, or substituted or unsubstituted cyclooctyl; or R 8 , R 10 , R 12 , and R 14 are each independently substituted or unsubstituted tetrahydrofuranyl, substituted or unsubstituted tetrahydrothiophenyl, substituted or unsubstituted pyrrolidinyl, substituted or unsubstituted 1,3-dioxolanyl, substituted or un
Antineoplastic agents · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.